Chemical Synthesis Core

通常情况下，要么是需要援助的PI，要么是药物开发协作组(DDC)将项目带到核心中心进行考虑。DDC(由Patricia Steig博士和Doug Figg博士担任主席)是一个指导委员会，为CCR研究人员的项目提供援助，以支持临床前开发。DDC提交的项目通常需要重新合成或简单的药物化学，以使项目在开发中向前推进。在Core同意承担项目之前，PI向合成团队正式提交项目，以确定化学、合成可行性、成本、完工时间和替代商业/供应商选项。在PI会议之前，合成团队已经确定了拟议的合成和/或探索了供应商选项。在PI会议期间，决定核心是否将承担该项目或推荐替代方法。特定项目的范围是与上下文相关的。有些项目只是简单的“受雇合成”，而其他项目则更具协作性，涉及共同撰写出版物。乔尔·施耐德积极管理项目。核心小组会议每周在弗雷德里克举行一次，讨论进展情况、排除化学故障并审查分析数据。当需要时，会咨询Jay Schnekloth博士和Martin Schnermann博士来制定合成策略。两位PI都接受过合成方法学和天然产物合成方面的特殊培训。

Typically, either a PI in need of assistance or the Drug Development Collaborative (DDC) brings projects to the Core for consideration. The DDC (chaired by Drs. Patricia Steeg and Doug Figg) is a steering committee that provides CCR investigators with assistance in their projects to support pre-clinical development. Projects presented by the DDC are typically in need of re-synthesis or simple medicinal chemistry that will allow the project to move forward in development. Before the Core agrees to undertake the project, the PI presents the project formally to the synthesis team to define the chemistry, synthetic feasibility, cost, time-to-completion, and alternate commercial/ vendor options. Prior to the PI meeting, the synthetic team will have already determined a proposed synthesis and/or explored vendor options. During the PI meeting, a decision is made as to whether or not the Core will undertake the project or recommend an alternate approach. The scope of a particular project is contextual. Some projects are simply "synthesis for hire" and others are more collaborative in nature and involve co-authoring publications. Joel Schneider actively manages projects. Core group meetings are held in Frederick once a week to discuss progress, troubleshoot chemistry and review analytical data. When needed, Drs. Jay Schneekloth and Martin Schnermann are consulted to develop synthetic strategy. Both PIs have exceptional training in synthetic methodology and natural product synthesis.